␣ 2 adrenergic agonists are used in the anesthetic management of the surgical patient for their sedative/hypnotic properties although the ␣ 2 adrenoceptor subtype responsible for these anesthetic effects is not known. Using a gene-targeting strategy, it is possible to specifically reduce the expression of the individual adrenoceptors expressed in the central nervous system and to thereby determine their role in hypnotic action.
Introduction
Despite the fact that general anesthetics have been in use for more than 150 yr, knowledge of the biochemical and neurochemical mechanisms underlying the anesthetic state is lacking. In an attempt to shed light on this problem, we and others (1) have turned to receptor-specific agents, including ␣ 2 adrenergic agonists, to dissect the discrete brain regions and molecular components which are involved in anesthetic responses. Using dexmedetomidine, a highly selective ␣ 2 adrenergic agonist, we demonstrated that the hypnotic response is transduced in the locus coeruleus (LC) 1 (2) and involves an ␣ 2 adrenoceptor coupled to a pertussis toxin-sensitive G protein (3) which inhibits adenylate cyclase (4) . The resulting decrease in activation of cAMP-dependent protein kinase modulates various ion channels (5) .
Clinical studies with ␣ 2 adrenergic agonists have revealed its putative utility in the perioperative period (6) , but its attendant cardiovascular side effects have curtailed widespread application of this class of drug to anesthesia. Responses to the clinically available ␣ 2 agonists, both beneficial and unwanted, are mediated by activation of one or more of the three ␣ 2 adrenoceptor subtypes since none of these compounds have subtype selectivity. Future drug development in this class will need to target the anesthesia-mediating subtype while avoiding activation of the other subtype(s); such a strategy may mitigate the cardiovascular side effects.
Molecular genetic cloning studies in humans, rats, and mice have shown that three genes encode distinct ␣ 2 adrenergic receptor subtypes (Table I) . Pharmacological studies have defined four subtypes named ␣ 2A , ␣ 2B , ␣ 2C , and ␣ 2D , with the ␣ 2D representing a species homologue of ␣ 2A (the term ␣ 2A will be used to designate the ␣ 2A/D subtype). The three ␣ 2 adrenergic receptor subtypes are nonhomogeneously distributed in the central nervous system (7) (8) (9) (10) (11) (12) (13) (14) (15) with the ␣ 2A and ␣ 2C subtypes predominating while the ␣ 2B subtype is sparsely represented and only in the diencephalon (16) . In this study, using antisense oligodeoxynucleotide (ODN) technology (17-21), we establish that the ␣ 2A is the subtype mediating the hypnotic response to dexmedetomidine in the LC.
Methods
Synthesis of oligonucleotides. The phosphodiester ODNs were synthesized on ABI 394 and ABI 380B DNA Synthesizer by use of phosphoramidite chemistry (PAN Facility, Stanford, CA). The introduction of phosphorothioate linkages (S-ODNs) were achieved by using tetraethylthiuram disulfide reagent (Applied Biosystems, Inc., Foster City, CA). The S-ODNs were purified over NAP-10 (Pharmacia Biotech, Uppsala, Sweden) and quantitated by spectrophotometry.
The sequences in the region immediately downstream from the initiation codon of rat ␣ 2A and ␣ 2C adrenoceptor subtypes were targeted. "Scrambled" ODNs containing the same nucleotides, but rearranged, were used as controls. The sequences of ODNs used in this study were: rat ␣ 2A antisense, 5 Ј -ATG,GGC,TCC,CTG,CAG,CCG,GAT-3 Ј ; rat ␣ 2A scrambled antisense, 5 Ј -CGA,GTT,GCC,TCA,AGC,GGT,CGC-3 Ј ; rat ␣ 2C antisense, 5 Ј -ATG,GCG,TCC,CCA,GCG,CT-3 Ј ; rat ␣ 2C scrambled antisense, 5 Ј -GGC,CTC,ACT,GCG,ACG,TC-3 Ј .
In vitro exposure of ODNs to cells stably transfected with either ␣ 2A and ␣ 2C receptor subtypes. PC 124D cells, stably transfected with rat ␣ 2A adrenoceptors, and NIH3T3 cells stably transfected with rat ␣ 2C adrenoceptors were kindly provided by Dr. Stephen M. Lanier (22) . These cell lines were maintained in monolayer culture at 37 Њ C, under an atmosphere of 5% CO 2 . For the PC124D cells, RPMI 1640 medium was supplemented with 10% dialyzed fetal bovine serum plus 5% horse serum. In NIH3T3 cells, Dulbecco's modified Eagle's medium (DME) was supplemented with 10% bovine calf serum. All media were additionally supplemented with penicillin (100 U/ml), streptomycin (100 mg/ml), and fungizone (0.25 mg/ml). The culture media with 5 M phosphorothioate ODNs (antisense and scrambled) or saline were changed twice a day for 3 d. On day 4, the cells were harvested for assessment of receptor expression.
Radiolabeled ligand binding assays. These were performed as described previously (23) . Briefly, cells were rinsed twice with cold PBS and then 10 ml of ice-cold lysis buffer (10 mM Tris-HCl, pH 7.4, 1 mM EDTA) was added. Cells were scraped off the flask with a disposable "policeman" and collected. The flask was rinsed with an additional 5 ml of lysis buffer and the washings were pooled. Cells were homogenized by four 5-s bursts at full speed using a polytron. The nuclei were pelleted by centrifugation at 220 g for 5 min at 4 Њ C and the supernatant was centrifuged at 16,000 rpm (Sorvall) in SS34 rotor for 30 min. The pelleted membranes were resuspended in an appropriate volume of binding buffer (75 mM Tris-Cl, 12.5 mM MgCl 2 , 1 mM EDTA, pH 7.4) aliquoted into 1-ml screw-capped Eppendorf tubes, and stored in liquid nitrogen.
Binding experiments were performed in 0.25-ml volumes of buffer for 90 min at 25 Њ C, using [ 3 H]atipamezole (82 Ci/mmol; Orion Farmos, Turku, Finland) as the ␣ 2 ligand. The assays were performed on between 5 and 100 g of membrane protein (determined by BioRad's dye-binding reagent). The bound radiolabeled ligand was separated from the free ligand by filtration through GF/C filters using a vacuum filtration manifold (Brandel Cell Harvester). Saturation binding isotherms were performed by incubating membranes with varying concentrations of the radioligand, and nonspecific binding was determined by adding 10 M rauwolscine. Equilibrium dissociation constants were determined from saturation isotherms using a nonlinear least-square curve-fitting technique (GraphPAD Software Inc., San Diego, CA). Protein content for the membrane preparations were assayed according to Lowry et al. (24) . B max was calculated in fmol/mg protein and was expressed as percent B max of the control.
In vivo studies. The experimental protocol was approved by the Animal Care and Use Committee at the Veterans Affairs Palo Alto Health Care System. Male Sprague-Dawley rats, originating from the same litter, weighing 250-350 grams, were used. The rats were stratified to match the distribution of the weights in the groups as closely as possible. All tests were performed between 10 a.m. and 4 p.m. The number of animals for each experiment is listed in the legends.
The left LC was stereotactically cannulated with a 24 gauge stainless steel cannula according to the following coordinates: with the bregma as the reference, 1.2 mm lateral, 9.7 mm posterior, and at a depth of 6 mm from the skull. The surgical procedure was performed with the rat under halothane anesthesia and the cannula was fixed in position with methylmethacrylate resin. Correct placement of the cannula at the superior border of the LC was by the appropriate hypnotic response to dexmedetomidine (2) . Cannulated rats were injected three times, on alternate days (days 1, 3, and 5), with 5 nmol/ 0.2 l of phosphodiester antisense, its scrambled control ODNs, or 0.2 l saline. The hypnotic response was determined before antisense treatment, just after the treatment (on day 6), and 8 d after the last antisense treatment. The treatment times were predicated by the t 1/2 of 4 d for the ␣ 2A adrenoceptor in the rat cortex (25) . Dexmedetomidine, 7.0 g in 0.2 l, was administered into the LC with a microinfusion pump (CMA, West Lafayette, IN). The hypnotic response was defined by the loss of the rat's righting reflex (LORR); both the latency (time from injection until the animal first lost its righting reflex) and duration (time from the rat's inability to right itself when placed on its back until the time that it spontaneously reverted, completely, to the prone position) were measured. The observer was blinded to the various treatments.
Statistical analysis. The data are expressed as mean Ϯ SEM. The results of the in vitro experiments are analyzed by one-way ANOVA, followed by Newman-Keul's test. The results of the in vivo experiments are analyzed by two-way ANOVA with repeated measures, followed by Bonferroni test. P Ͻ 0.05 is considered statistically significant.
Results

Effect of ODNs on receptor expression in vitro.
Compared with the saline control, the ␣ 2A antisense ODNs significantly ( P Ͻ 0.05) reduced the mean B max value of ␣ 2A adrenoceptors on PC124D cells by Ͼ 30%; neither ␣ 2A scrambled ODNs (94.0%) nor ␣ 2C antisense ODNs (98.2%) had any significant effects on the mean B max value on PC124D cells (Fig. 1, n ϭ 4) .
Compared with the saline control, the ␣ 2C antisense ODNs significantly ( P Ͻ 0.01) reduced the mean B max value of ␣ 2C (Fig. 2, n ϭ 4, respectively) .
Effect of ODNs on hypnotic response to dexmedetomidine. Immediately after ␣ 2A antisense treatment, duration of LORR was significantly decreased when compared with the values before and 8 d after antisense treatment (Fig. 3 A, n ϭ 5) . Conversely, no changes in the duration of LORR were noted in animals treated with either the saline vehicle or scrambled ␣ 2A antisense. The latency until LORR increased significantly immediately after ␣ 2A antisense treatment when compared with the values before and 8 d after antisense treatment ( Fig. 3 B) ; again, no changes in the duration of LORR was noted in animals treated with either the saline vehicle or scrambled ␣ 2A antisense. Neither the duration (Fig. 4 A) nor the latency (Fig. 4 B) of LORR was affected by the ␣ 2C antisense ODNs or its scrambled ␣ 2C antisense ODNs.
Discussion
Antisense ODNs selectively and specifically decreased receptor subtype expression in vitro. Antisense ODNs for the ␣ 2A receptor subtype decreased the hypnotic response to dexmedetomidine in a reversible manner. Neither the scrambled ␣ 2A ODNs nor the antisense ODNs for the ␣ 2C receptor subtype affected the hypnotic response to dexmedetomidine. While we do not provide evidence that in vivo expression of the ␣ 2A receptor subtype is reversibly altered, our in vitro biochemical and in vivo behavioral findings strongly implicate the ␣ 2A receptor subtype in the mediation of the hypnotic response to ␣ 2 agonists in the LC. Attempts to assess receptor expression in the minute LC were thwarted by the absence of appropriate antibodies to discriminate between the two ␣ 2 receptor subtypes.
The antisense ODNs possess unique sequences relative to the entire genome. Therefore, antisense ODN technology provides a degree of specificity which is lacking in conventional pharmacologic or toxicologic probes (26) . Inhibition of receptor expression by antisense ODNs relies on the ability of an ODN to bind a complementary sense mRNA sequence and prevent translation of the mRNA. Among the possible mechanisms whereby this interferes with protein expression is the presence of the ubiquitous H RNAse which can digest the RNA-DNA duplex making the mRNA transcript unavailable for translation (27) . The level of the expressed protein will decrease and therefore the function propagated by the protein will be lacking. The effect on protein expression is usually incomplete unless the ODNs are continuously delivered over a prolonged period of time, usually four times the t 1/2 of the protein. The turnover rate of the rat ␣ 2A adrenoceptor is thought to be ‫ف‬ 4 d (28) . If the remaining protein exceeds the threshold required to produce a functional response, the decrement in protein expression will not be functionally noticed. Such "redundancy" exists to varying degrees for each of the behavioral responses to ␣ 2 agonists, as determined by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) studies (29) . However, a 25%, or greater, decrement in receptor expression was found to be sufficient to attenuate the hypnotic response. A robust feature of an in vivo antisense ODN study is that the effect should be reversible over a time course predicated by the protein kinetics. The fact that the response is reversible assures one that the effect is not due to nonspecific antisense toxicity and provides a degree of specificity which is lacking in "knockout" or "transgenic" experiments unless complemented by subsequent breeding studies to reacquire the original phenotype. There are now several examples in which antisense ODNs have been successfully used in vivo to interfere with specific protein synthesis and its physiologic function (17) (18) (19) (20) (21) .
Using a knockout gene-targeting strategy, work from Kobilka's lab (30) has demonstrated that, unlike the wild-type, mice deficient in the ␣ 2B adrenoceptor subtype do not exhibit the acute hypertensive response to a bolus dose of dexmedetomidine. While knockout strategies have failed to yield mice deficient in the ␣ 2A adrenoceptor subtype, recent transgenic experiments have developed mice with "dysfunctional" ␣ 2A adrenoceptors. Data from behavioral studies on these mice also implicate this receptor subtype for the anesthetic action to dexmedetomidine (MacMillan, L.B., T.-Z. Guo, L.E. Limbird, and M. Maze, manuscript in preparation).
The ␣ 2 adrenergic agonists are currently being used in the anesthetic management of the surgical patient for their sedative/hypnotic, anesthetic-sparing, analgesic, and sympatholytic properties. Each of the clinically available agents in this class has an imidazole ring which facilitates activation of nonadrenergic imidazoline binding sites; neither do they discriminate between the three ␣ 2C adrenoceptor subtypes. This relative nonspecificity and nonselectivity of the clinically available agonists may be the cause of troublesome side effects. For example, the vagally mediated bradycardia may be due, in part, to activation of the imidazoline-preferring receptor in the brain stem (31). Also, the acute hypertension that follows rapid bolus administration of ␣ 2 agonists is probably due to activation of the ␣ 2B adrenoceptor subtype (30). Full realization of the clinical potential of this drug class for anesthesia will require the synthesis of novel ligands which have specificity for the receptor subtype(s) responsible for the salubrious effects while avoiding affinity for sites capable of producing side effects. Therefore, it is important to define, unequivocally, the receptor subtype(s) responsible for the anesthesia-related properties. This study taken together with the recent knockout and transgenic studies suggests that the ␣ 2A adrenoceptor subtype should be the target for subsequent drug development of ␣ 2 agonists for anesthetic use. 
